Crinetics Pharmaceuticals Stock Price, News & Analysis

Crinetics Pharmaceuticals (Nasdaq: CRNX) announced on July 10, 2024, that it has granted non-qualified stock options to purchase a total of 137,900 shares of common stock to 18 new non-executive employees. These grants are part of the 2021 Employment Inducement Incentive Award Plan and align with Nasdaq Listing Rule 5635(c)(4). The exercise price for these options is set at $50.80 per share, matching the closing price on July 10, 2024. The stock options will vest over four years, with 25% vesting after one year and the remaining 75% vesting in 36 monthly installments, contingent upon continued employment.

Scott Struthers, Ph.D., CEO and founder of Crinetics Pharmaceuticals, has been named the Entrepreneur Of The Year® 2024 Pacific Southwest Award winner by Ernst & Young LLP (EY US). This award honors leaders who disrupt markets and create significant value. This recognition highlights Struthers' entrepreneurial spirit and the impactful work of Crinetics in developing novel therapeutics for endocrine diseases. Crinetics' lead drug candidate, paltusotine, is on track for a New Drug Application submission with the FDA by the end of 2024. Struthers will now be considered for the national awards, with winners to be announced in November. The award program celebrates diverse entrepreneurial leaders, including original founders and transformational CEOs, and provides access to a global community and vast EY resources.

Crinetics Pharmaceuticals announced on June 10, 2024, that its Compensation Committee granted non-qualified stock options to purchase a total of 158,000 shares to nine new non-executive employees. This is part of the company's 2021 Employment Inducement Incentive Award Plan, designed to attract new talent. The stock options, priced at $45.01 per share, will vest over four years. The plan follows Nasdaq Listing Rule 5635(c)(4), offering equity awards to new employees as a material inducement for joining Crinetics.

Crinetics has announced positive initial findings from two ongoing open-label studies of its drug candidate atumelnant (CRN04894) for treating congenital adrenal hyperplasia (CAH) and ACTH-dependent Cushing's syndrome (ADCS). In the CAH study, all participants (n=6) maintained androstenedione (A4) below normal levels, with more than 90% reduction in A4 and 97% reduction in 17-OHP sustained through 12 weeks. In the ADCS trial, atumelnant normalized 24-hour urinary free cortisol levels for all participants (n=5) within the treatment period. The studies reported no severe or serious adverse events. A conference call for investors is scheduled for June 3, 2024, highlighting these initial results and further developments.

Crinetics presented new data at ENDO 2024, showcasing once-daily oral paltusotine as a potential first-choice treatment for acromegaly.

Results from Phase 3 PATHFNDR-2 trial indicated significant efficacy, with 56% of participants achieving normal IGF-1 levels versus 5% on placebo. Paltusotine showed rapid and sustained IGF-1 reduction, with 92.6% of patients responding by end of treatment. The drug was well tolerated with no serious adverse events.

PATHFNDR-1 trial data revealed paltusotine reduced daily breakthrough symptom exacerbations compared to standard injections. Long-term data from the ACROBAT Advance study showed durable safety and efficacy over 42 months.

Crinetics plans to submit a New Drug Application in the second half of 2024.

Crinetics Pharmaceuticals (Nasdaq: CRNX) announced the appointment of Dr. Robert M. Cuddihy as Senior Vice President of Medical Affairs. Dr. Cuddihy brings over 30 years of experience in endocrinology, diabetes, and metabolism, with expertise in both clinical practice and the pharmaceutical industry. He previously served in key roles at Dartmouth Hitchcock Medical Center and Clinics, Amgen, Janssen, Sanofi, and Capsida Biotherapeutics. CEO Scott Struthers emphasized Dr. Cuddihy's ability to enhance the company's development and commercialization efforts for its investigational products, paltusotine and atumelnant, and its discovery pipeline. Dr. Cuddihy expressed enthusiasm for advancing therapies targeting endocrine diseases.

Crinetics Pharmaceuticals (Nasdaq: CRNX) announced the early release of late-breaking abstracts for ENDO 2024, focusing on a Phase 2 study of atumelnant (CRN04894) for Congenital Adrenal Hyperplasia (CAH). Initial data from four subjects were submitted, with plans to present extended results from six subjects in cohort 1 and more in cohort 2 at ENDO 2024. Detailed findings will be shared on June 3, 2024, during the Late-Breaking Poster Presentation session.

Crinetics Pharmaceuticals announced on May 10, 2024, the granting of non-qualified stock options to fifteen new non-executive employees under the 2021 Employment Inducement Incentive Award Plan. The options have an exercise price of $48.00 per share and will vest over four years. This inducement is pursuant to Nasdaq Listing Rule 5635(c)(4).

Crinetics Pharmaceuticals reported strong financial results for Q1 2024, highlighted by positive data from Phase 2 studies of Atumelnant (CRN04894) in congenital adrenal hyperplasia and ACTH-dependent Cushing’s Syndrome. The company is set to present late-breaking results at ENDO in June. Additionally, a Phase 3 study for paltusotine in carcinoid syndrome is expected to start by year-end. Crinetics also secured $350 million in financing to support commercial readiness and pipeline development, totaling $901.0 million in cash and equivalents as of March 31, 2024.